Pharmaceutical News

RSS

Experimental cancer drug shows promise against incurable paediatric brain cancer

US-Australian drug discovery company, Novogen Limited, in conjunction with Australian paediatric cancer researchers, released key pre-clinical data on experimental cancer drug-candidate, TRXE-009, confirming its potential to become an important new therapy against an incurable paediatric brain cancer called DIPG (diffuse intrinsic pontine glioma).

8 May 2015

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Australian biopharmaceutical company Specialised Therapeutics Australia and Helsinn, a Swiss group focused on building quality cancer care, announce that the Therapeutic Goods Administration has approved AKYNZEO for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy.

8 May 2015

Using mobile app to track intake of vitamin D and calcium

Vitamin D is essential for the maintenance of bone health and may be implicated in other chronic diseases, as well as immunity, but adults in Canada are consistently deficient in dietary vitamin D, by nearly 400 international units per day (IU/d) on average.

8 May 2015

Study confirms link between statin drugs and diabetes risk

In a database study of nearly 26,000 beneficiaries of Tricare, the military health system, those taking statin drugs to control their cholesterol were 87 percent more likely to develop diabetes.

8 May 2015

Cancer drugs get quick approvals despite little effect on patients, says York U researcher

Highly priced cancer drugs get rushed approvals despite poor trial methodology and little effect on the longevity of patients, cautions York University Professor Dr. Joel Lexchin in the School of Health Policy and Management.

8 May 2015

New compound offers longer lasting painkilling effects

Medications have long been used to treat pain caused by injury or chronic conditions. Unfortunately, most are short-term fixes or cause side effects that limit their use. Researchers at the University of Missouri have discovered a new compound that offers longer lasting painkilling effects, and shows promise as an alternative to current anesthetics.

7 May 2015

New epilepsy drug holds promise as Alzheimer's treatment

University of British Columbia researchers say a new epilepsy drug holds promise as a treatment for Alzheimer's disease.

7 May 2015

Cyclenium Pharma, Haplogen sign agreement to discover novel pharmaceutical candidates

Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the research and development of novel drug candidates based on its proprietary macrocyclic chemistry technology, and Haplogen GmbH, a biotechnology company developing anti-infective drugs, today announced the signing of a research agreement aimed at the discovery of novel pharmaceutical candidates in multiple disease areas.

7 May 2015

Omega-3 fatty acids in fish oil can restore nerves damaged from diabetes

Approximately 50 percent of patients with diabetes suffer from nerve damage, or neuropathy. No cure exists, and the most effective treatment, keeping blood sugar in control, only slows neuropathy.

7 May 2015

Global haemophilia therapeutics market estimated to reach $13.43 billion in 2019

Increased uptake of recombinant therapies and prophylactic use, coupled with improved diagnosis of haemophilia, is expected to drive the associated therapeutics market. Recombinant therapies are likely to command a premium price and fuel growth in developed markets, while heightened access to treatment and larger patient volumes due to more funding for critical care are anticipated to contribute to demand in emerging markets.

7 May 2015

Preterm babies treated with bevacizumab for severe retinopathy of prematurity have lower motor scores

Preterm babies with retinopathy of prematurity (ROP) treated using bevacizumab, a growth inhibitor, have been found to have lower motor scores than babies treated with traditional laser ablation. The research is being presented at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology this week in Denver, Colo.

7 May 2015

Cardiff scientists develop novel anti-cancer stem cell compound

Cardiff University scientists have developed a novel anti-cancer stem cell agent capable of targeting aggressive tumour forming cells common to breast, pancreas, colon and prostate cancers.

7 May 2015

Treatment significantly reduces risk of CDI recurrence

Among patients with Clostridium difficile infection (CDI) who recovered following standard treatment with the antibiotics metronidazole or vancomycin, oral administration of spores of a strain of C difficile that does not produce toxins colonized the gastrointestinal tract and significantly reduced CDI recurrence, according to a study in the May 5 issue of JAMA.

7 May 2015

Parkinson's disease drug delays onset of age-related macular degeneration

L-DOPA, a routine drug taken by patients suffering from Parkinson's disease, has been found to delay the onset of age-related macular degeneration (AMD). The research is being presented at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology this week in Denver, Colo.

6 May 2015

AbbVie's venetoclax granted FDA Breakthrough Therapy Designation for CLL patients with 17p deletion

AbbVie today announced its investigational medicine venetoclax, an inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, has been granted Breakthrough Therapy Designation by the FDA for the treatment of chronic lymphocytic leukemia (CLL) in previously treated (relapsed/refractory) patients with the 17p deletion genetic mutation.

6 May 2015

Cipher strengthens Canadian dermatology portfolio with acquisition of Vaniqa, Actikerall

Cipher Pharmaceuticals Inc. today announced it has strengthened its Canadian dermatology portfolio by acquiring the Canadian rights to Vaniqa and Actikerall from Almirall S. A., a Spanish pharmaceutical company. Both products have been approved by Health Canada.

6 May 2015

Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of gastric cancers

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted an Orphan Drug Designation (ODD) for its lead product candidate, REOLYSIN, for the treatment of gastric cancers.

6 May 2015

Transition Therapeutics acquires worldwide rights from Lilly to develop, commercialize TT701

Transition Therapeutics Inc. today announced its wholly-owned subsidiary, Transition Therapeutics Ireland Limited, has exclusively licensed worldwide rights to a novel small molecule drug candidate ("TT701") from Eli Lilly and Company.

6 May 2015

Weston Park Hospital offers two cutting-edge treatments for rare cancer tumours, prostate cancer

TWO cutting-edge cancer treatments using targeted radioactive therapy injections to destroy cancer cells are now being offered to patients with rare neuroendocrine tumours and patients with prostate cancer at Weston Park Hospital.

6 May 2015

Johns Hopkins researchers develop new strategies to treat depression in children, adolescents

A multidisciplinary team of Johns Hopkins researchers has developed two new strategies to treat depression in young people using the selective serotonin reuptake inhibitor (SSRI) class of medications. These strategies, published May 5 in the journal Translational Psychiatry, incorporate a new understanding of how to mitigate the risk of suicide while on SSRI treatment.

6 May 2015

Pharmaceutical News

Experimental cancer drug shows promise against incurable paediatric brain cancer

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Using mobile app to track intake of vitamin D and calcium

Study confirms link between statin drugs and diabetes risk

Cancer drugs get quick approvals despite little effect on patients, says York U researcher

New compound offers longer lasting painkilling effects

New epilepsy drug holds promise as Alzheimer's treatment

Cyclenium Pharma, Haplogen sign agreement to discover novel pharmaceutical candidates

Omega-3 fatty acids in fish oil can restore nerves damaged from diabetes

Global haemophilia therapeutics market estimated to reach $13.43 billion in 2019

Preterm babies treated with bevacizumab for severe retinopathy of prematurity have lower motor scores

Cardiff scientists develop novel anti-cancer stem cell compound

Treatment significantly reduces risk of CDI recurrence

Parkinson's disease drug delays onset of age-related macular degeneration

AbbVie's venetoclax granted FDA Breakthrough Therapy Designation for CLL patients with 17p deletion

Cipher strengthens Canadian dermatology portfolio with acquisition of Vaniqa, Actikerall

Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of gastric cancers

Transition Therapeutics acquires worldwide rights from Lilly to develop, commercialize TT701

Weston Park Hospital offers two cutting-edge treatments for rare cancer tumours, prostate cancer

Johns Hopkins researchers develop new strategies to treat depression in children, adolescents

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News